Pharma Mar, S.A. (PHMMF) Stock

About Pharma Mar, S.A.

Pharma Mar, S.A. is a biopharmaceutical firm dedicated to the discovery, development, manufacturing, and commercialization of bioactive compounds derived from marine organisms, primarily targeting oncology applications. Its products and research initiatives reach across key markets including Spain, Italy, Germany, Ireland, the broader European Union, the United States, and other international territories. The company's operations are structured across three distinct segments: Oncology, Diagnostics, and RNA Interference. Within its oncology portfolio, Pharma Mar markets Yondelis®, prescribed for soft tissue sarcomas and ovarian cancer, alongside Aplidin® for multiple myeloma, and Zepzelca®, which addresses small cell lung cancer. Additionally, the company has PM14, currently undergoing Phase II clinical trials for the treatment of various solid tumors. Beyond oncology, the Diagnostics segment is involved in the development and sale of diagnostic kits. Furthermore, through its RNA Interference division, Pharma Mar is advancing therapeutics designed to modulate or silence gene expression for therapeutic benefit. Established in 1986, the company maintains its headquarters in Madrid, Spain.

Pharma Mar, S.A. is headquartered in ES.

Pharma Mar, S.A. (PHMMF) stock trades at $86.09 with a market capitalization of $1.49B. The stock is valued at a price-to-earnings (P/E) ratio of 16.95, price-to-book of 5.43, price-to-sales of 6.06. Over the past 52 weeks the stock has ranged between $77.41 and $110.40, and currently trades 22.0% below its 52-week high. It pays a dividend yielding 1.32%.

On profitability, Pharma Mar, S.A. generates a return on equity (ROE) of 35.74% — well above the market average, a sign of a high-quality business, return on capital employed of 19.89%, an operating margin of 26.12%, a net profit margin of 35.70%.

Official website: www.pharmamar.com